Articles

ORLANDO—More education about assessment and management of cardiotoxicity would strengthen the quality of nursing care of cancer patients, according to a new study.

Read More ›

MILAN—Prolonging chemotherapy until disease progression improves progression free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer (MBC), according to a systematic analysis presented at the 35th European Society for Medical Oncology Congress.

Read More ›

SAN DIEGO—Omitting adjuvant tamoxifen may not put women aged older than 65 years with early-stage breast cancer at increased risk for local or distant disease recurrence, according to a large, retrospective study presented at the 52nd annual meeting of the American Society for Radiation Oncology.

Read More ›

MILAN—The investigative poly (ADPribose) polymerase (PARP) inhibitor iniparib (BSI-021) im proved not only progression-free survival (PFS) but also overall survival (OS) in the final analysis of a randomized phase 2 study, presented at the 35th European Society for Medical Oncology Congress by Joyce O’Shaughnessy, MD, of US Oncology and Baylor Sammons Cancer Center, Houston.

Read More ›

SAN DIEGO—Elizabeth Brunton, RN, MSN, OCN, started in the nursing field in 1973. More than 35 years later, she is the recipient of the American Society for Radiation Oncology (ASTRO) Nurse Excellence Award. This award is presented annually to a registered nurse who goes above and beyond the normal standards of nursing practice.

Read More ›

This past April, Geisinger Medical Center’s (GMC) Cancer Institute became one of 14 sites added to the National Cancer Institute Community Cancer Centers Program (NCCCP). Joining this national network of community cancer centers offers GMC the opportunity to expand its state-of-the-art cancer care and research in northeast Pennsylvania.

Read More ›

Women with breast cancer who have elevated levels of C-peptide (a marker of insulin secretion) have significantly higher mortality rates than their peers with lower levels, results of the Health, Eating, Activity, and Lifestyle (HEAL) study indicate.
 
Read More ›

Oral rivaroxaban’s efficacy at reducing the risk of recurrent venous thromboembolism (VTE) was confirmed in two trials presented at the annual meeting of the American Society of Hematology. The agent was studied for treatment of deep-vein thrombosis (DVT) as well as for continued therapy after initial anticoagulation treatment for DVT or pulmonary embolism.
 
Read More ›

For patients with a past history or family history of colorectal cancer, annual fecal immunochemical tests (FITs) detect neoplasias sooner than scheduled 10-year colonoscopies, according to a new study published in the December issue of Gastroenterology. For patients with FIT-positive results, diagnosis was made sooner by 25 months for cancer and by 24 months for advanced adenomas.
 
Read More ›

Researchers have confirmed the long-term benefits of adjuvant anastrozole to help stop recurrence of breast cancer in postmenopausal women with hormone-sensitive early breast cancer, according to a 10-year analysis of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial published in The Lancet Oncology (Nov 16, 2010. Epub ahead of print).
 
Read More ›

Page 357 of 377


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: